A recent court decision in the United States has forced Japanese drugmaker Takeda to report a significant financial loss for the fiscal year ending March 2026. The company now faces a loss of 152 billion Japanese yen (about $950 million), an adjustment from an earlier profit estimate of 192 billion yen ($1.2 billion). This change was necessary because of a jury verdict last month in a lawsuit involving allegations that Takeda delayed the release of a generic version of its constipation drug, Amitiza. The lawsuit was filed by pharmacies, health insurance companies, and other healthcare providers who claim Takeda worked with a partner to keep cheaper generic versions of Amitiza off the market for as long as possible. According to the lawsuit, this delay forced them to pay higher prices for the medication. The court ordered Takeda to pay at least $885 million in damages, though this amount could triple to $2.5 billion under U.S. antitrust laws. Takeda plans to appeal the decision and believes the case has serious legal flaws. The company has already set aside 402.5 billion yen ($2.5 billion) in its financial reports to cover potential legal costs, even though the final damage amount has not been decided yet. Despite this legal challenge, Takeda’s total revenue for the year remained strong at 4.5 trillion yen ($28 billion). Looking ahead, the company expects to return to profitability in the next fiscal year, with revenue projected at 4.64 trillion yen ($28.9 billion). Takeda is also preparing to launch three new medications in 2026, including treatments for narcolepsy, polycythemia vera, and psoriasis. Additionally, the company is implementing a major cost-saving plan that aims to cut more than 200 billion yen ($1.26 billion) in expenses annually by 2028 and will reduce its workforce by about 4,500 positions over the next two years. Takeda has stated that this legal issue does not affect its long-term business plans or financial guidance for the upcoming year.